AI Article Synopsis
- KRAS, a key player in tumor development, activates additional pathways beyond MAPK and PI3K, which are crucial for tumor maintenance.
- Researchers found that the kinases TBK1 and IKKε support KRAS-driven tumor growth by regulating the release of cytokines like CCL5 and IL-6.
- The drug CYT387 effectively inhibits these signaling pathways, leading to reduced tumor growth and enhanced treatment effects when combined with MAPK inhibition in mouse models of lung cancer.
Article Abstract
Although the roles of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signaling in KRAS-driven tumorigenesis are well established, KRAS activates additional pathways required for tumor maintenance, the inhibition of which are likely to be necessary for effective KRAS-directed therapy. Here, we show that the IκB kinase (IKK)-related kinases Tank-binding kinase-1 (TBK1) and IKKε promote KRAS-driven tumorigenesis by regulating autocrine CCL5 and interleukin (IL)-6 and identify CYT387 as a potent JAK/TBK1/IKKε inhibitor. CYT387 treatment ablates RAS-associated cytokine signaling and impairs Kras-driven murine lung cancer growth. Combined CYT387 treatment and MAPK pathway inhibition induces regression of aggressive murine lung adenocarcinomas driven by Kras mutation and p53 loss. These observations reveal that TBK1/IKKε promote tumor survival by activating CCL5 and IL-6 and identify concurrent inhibition of TBK1/IKKε, Janus-activated kinase (JAK), and MEK signaling as an effective approach to inhibit the actions of oncogenic KRAS.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980023 | PMC |
| http://dx.doi.org/10.1158/2159-8290.CD-13-0646 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The role of silent mutations in KRAS-mutant tumors.
Chin Med J (Engl)
December 2024
Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Article Synopsis
- Silent mutations in the RAS gene, especially in KRAS, are gaining attention for their potential effects on cancer development and treatment strategies, despite being less studied than active mutations.
- These silent mutations don’t change protein sequences but can influence RNA stability and how effectively proteins are made, raising questions about their role in tumor biology.
- Exploring the implications of KRAS silent mutations could lead to new diagnostic tools and targeted therapies for cancer, highlighting the need for further research in this area.
A STAG2-PAXIP1/PAGR1 axis suppresses lung tumorigenesis.
J Exp Med
January 2025
Cancer Biology Program, Stanford University School of Medicine, Stanford, CA, USA.
The cohesin complex is a critical regulator of gene expression. STAG2 is the most frequently mutated cohesin subunit across several cancer types and is a key tumor suppressor in lung cancer. Here, we coupled somatic CRISPR-Cas9 genome editing and tumor barcoding with an autochthonous oncogenic KRAS-driven lung cancer model and showed that STAG2 is uniquely tumor-suppressive among all core and auxiliary cohesin components.
View Article and Find Full Text PDFInhibition of lung tumorigenesis by transient reprogramming in cancer cells.
Cell Death Dis
November 2024
Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
Article Synopsis
Unlabelled: Activating KRAS mutations are a key feature of pancreatic ductal adenocarcinoma (PDA) and drive tumor initiation and progression. However, mutant KRAS by itself is weakly oncogenic. The pathways that cooperate with mutant KRAS to induce tumorigenesis are less-defined.
View Article and Find Full Text PDFKRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development.
Oncogene
December 2024
Purdue University Interdisciplinary Life Sciences Program (PULSe), Purdue University, West Lafayette, IN, USA.
Oncogenic mutations in KRAS are present in ~95% of patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) and are considered the initiating event of pancreatic intraepithelial neoplasia (PanIN) precursor lesions. While it is well established that KRAS mutations drive the activation of oncogenic kinase cascades during pancreatic oncogenesis, the effects of oncogenic KRAS signaling on regulation of phosphatases during this process is not fully appreciated. Protein Phosphatase 2A (PP2A) has been implicated in suppressing KRAS-driven cellular transformation and low PP2A activity is observed in PDAC cells compared to non-transformed cells, suggesting that suppression of PP2A activity is an important step in the overall development of PDAC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!